Erasca, Inc. (ERAS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Erasca (ERAS) received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic cancer. The designation allows for accelerated regulatory review. In a Phase 1 trial, ERAS-0015 showed a 57% response rate in pancreatic cancer patients. The company plans to initiate pivotal trials in 2027. Q2 2026 R&D expenses rose to $35.9M, and net loss widened to $44.1M. Erasca raised $632.5M in July 2026, leaving it with $384.3M in cash.

Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.

Erasca (ERAS) reported a wider net loss of $287.223M in Q2 2026 and appointed Charles S. Fuchs as R&D president. The stock trades at $18.10, with 90-day and YTD returns of 55.97% and 404.18%, respectively. Despite a high P/B ratio of 17.5x, the company has no revenue and forecasts losses for the next three years. The article questions whether the stock is overvalued.

Erasca raised about $891.3M gross across two 2026 public offerings, including $632.5M in an upsized July offering and $258.8M in an upsized January offering. Cash was $384.3M as of June 30. The company says proceeds will fund accelerated development of ERAS-0015 and three potentially registration-enabling studies starting 2027-2028.

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Erasca Reports Second Quarter 2026 Business Updates and Financial Results Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC co

Erasca, Inc. (Nasdaq: ERAS) said it closed an upsized public offering of 36,142,857 shares of common stock at $17.50 per share, including 4,714,285 shares from the underwriters’ option. Gross proceeds were about $632.5 million. Erasca plans to use net proceeds for R&D, working capital, and general corporate purposes.